Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023)